Prof. dr. J.W. Jukema

Prof. dr. J.W. Jukema

Prof. dr. J.W. (Wouter) Jukema is opgeleid tot cardioloog in Amsterdam (Vrije Universiteit) en Leiden (Leids Universitair Medisch Centrum (LUMC) en is voorzitter van "Leiden Vascular Medicine" en "Established Clinical Investigator" van de Nederlandse Hartstichting. Tevens "founding director" van het in 2007 opgerichte "Durrer Institute for Cardiogenetic Research" in Amsterdam. Zijn promotieonderzoek "angiografic coronary atherosclerosis trials" verrichtte hij voornamelijk op het Interuniversitair Cardiologisch Instituut Nederland (ICIN) in Utrecht.

Zijn onderzoek en dagelijks werkt richt zich met name op athero-trombose, zowel (interventie) cardiologie als coronaire atherosclerose. Deze athero-trombose research focust op vasculaire biologie, lipoproteïnen en genetische achtergronden van athero-trombose en restenose/trombose na PTCA, zowel in mensen als in transgene dieren, en de meerderheid van zijn publicaties hebben dan ook betrekking op deze aandachtsgebieden. Hij is (hoofd)onderzoeker van meerdere internationale athero-trombose studies en lid van een aantal (inter)nationale athero-trombose- en lipiden vergaderingen.  

Top-cited publications

1616 times cited (±96/year) Source: EuropePMC

Lancet (London, England), Volume 360, Issue 9346, 01 November 2002, Pages 1623-1630 Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Abstract


1076 times cited (±126/year) Source: Scopus

Nature genetics, Volume 43, Issue 4, 06 March 2011, Pages 333-338 Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Schunkert H, König IR, Kathiresan S, Reilly MP, Assimes TL, Holm H, Preuss M, Stewart AF, Barbalic M, Gieger C, Absher D, Aherrahrou Z, Allayee H, Altshuler D, Anand SS, Andersen K, Anderson JL, Ardissino D, Ball SG, Balmforth AJ, Barnes TA, Becker DM, Becker LC, Berger K, Bis JC, Boekholdt SM, Boerwinkle E, Braund PS, Brown MJ, Burnett MS, Buysschaert I, Cardiogenics, Carlquist JF, Chen L, Cichon S, Codd V, Davies RW, Dedoussis G, Dehghan A, Demissie S, Devaney JM, Diemert P, Do R, Doering A, Eifert S, Mokhtari NE, Ellis SG, Elosua R, Engert JC, Epstein SE, de Faire U, Fischer M, Folsom AR, Freyer J, Gigante B, Girelli D, Gretarsdottir S, Gudnason V, Gulcher JR, Halperin E, Hammond N, Hazen SL, Hofman A, Horne BD, Illig T, Iribarren C, Jones GT, Jukema JW, Kaiser MA, Kaplan LM, Kastelein JJ, Khaw KT, Knowles JW, Kolovou G, Kong A, Laaksonen R, Lambrechts D, Leander K, Lettre G, Li M, Lieb W, Loley C, Lotery AJ, Mannucci PM, Maouche S, Martinelli N, McKeown PP, Meisinger C, Meitinger T, Melander O, Merlini PA Abstract


909 times cited (±95/year) Source: EuropePMC

Lancet (London, England), Volume 375, Issue 9716, 16 February 2010, Pages 735-742 Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Abstract


Most recent publications

02 Sep 2019

Circulation, 02 September 2019 Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, Zeiher AM, Baccara-Dinet MT, Steg PG, Schwartz GG, ODYSSEY OUTCOMES Investigators. Abstract


01 Sep 2019

Journal of the American College of Cardiology, Volume 74, Issue 9, 01 September 2019, Pages 1177-1186 Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery. Goodman SG, Aylward PE, Szarek M, Chumburidze V, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Hanotin C, Harrington RA, Jukema JW, Kedev S, Letierce A, Moryusef A, Pordy R, Ramos López GA, Roe MT, Viigimaa M, White HD, Zeiher AM, Steg PG, Schwartz GG, ODYSSEY OUTCOMES Committees and Investigators. Abstract


01 Sep 2019

European heart journal, Volume 40, Issue 33, 01 September 2019, Pages 2801-2809 Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG, ODYSSEY OUTCOMES Investigators. Abstract